×
020 3696 4080 info@idf.co.uk

Mantara Health

Mantara Health
Mantara Health

WHO WE ARE, HOW WE WORK AND WHY WE DO WHAT WE DO.


RIGHT DRUG RIGHT DOSE FIRST TIME:

As a business, we have to make pharmacogenomics (PGx) more accessible to everyone. We firmly believe that by offering clear information and guidance to people about the relevance and importance of this specialised genetic test, we will help them by guiding doctors to prescribe the safest and most personalised prescription for their patients’ particular medical needs.

As a true brand, Mantara really focusses on the things that matter. Understanding what our product is and how it can help you, to how we operate as a company, we are confident in who we are and what our mission is. We know how important our product is, why it is needed and we know how to help you.

Knowing what genes you have, that are involved specifically in how medications work in you, allows you the chance to get the right drug at the right dose first time. In so doing, the risk of side effects is minimised and the desired therapeutic outcome maximised. If a drug is influenced by your genes, why wouldn’t you want to know this information first?

Mantara is THE validated, trusted brand when it comes to truly personalised prescription medicine. Mantara is CE and UKCA marked and fully registered with the MHRA

Mantara has recently won the prestigious PING 2023 Innovation Award and 2023 StartUp Awards: MedTech & HealthTech Innovation.

Mantara PGx DNA Test is well placed in the growing demand for precision medicine, which tailors treatments to individual patients' genetics, resulting in better patient outcomes.

Our solution is to provide a genetic test to help healthcare providers determine the best medications and dosages for their patients based on their individual genetic profiles. This personalised approach to medicine can help reduce adverse drug reactions and improve treatment efficacy.

Right drug, Right dose, First time

We analyse genetic data to generate personalised medicine recommendations. We also have exclusive partnerships with a leading pharmacogenomic laboratory and digital health company to provide the most accurate and reliable testing.

Our analytic method is perfectly aligned with a major study published in The LANCET will supports the technology and the benefits of pre-emptive pharmacogenomic testing leading to a reduction in adverse drug reactions post prescribing of 30%. This would lead to significant improvements in healthcare.

In June 2023, NICE announced draft advice for pharmacogenomic testing introduction for anti-stroke drug clopidogrel (Mantara test for this drug as part of their panel) which is a major step forward in making pharmacogenomic testing available as a standard test on the NHS.

We currently cover 80+ medicines in our panel report covering 12 genes and include prescribing information on mental health, cardiovascular, stroke and several other therapeutic areas.

Mantara PGx DNA Test is the first to market a UKCA CE marked product and is registered with the MHRA as a medical device and complies with current regulations and also partnered with leading experts in pharmacogenomics to ensure the highest level of scientific rigour in our testing and analysis.